Research progress of hepatic steatosis evaluation evaluate in living donor liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2022.04.010

Abstract

Abstract:

Donor livers with steatosis as a type of marginal donor livers, has become an important channel to expand the source of donor livers. Therefore, it is important to evaluate the degree of steatosis before liver transplantation. The clinical judgment on the state of hepatic steatosis is based on the results of liver biopsy, but it brings a certain risk of trauma to patients. With the continuous development of imaging and biological detection technologies. The clinical methods including ultrasound, CT, MRI, magnetic resonance spectroscopy and biomarkers have been used to evaluate the degree of hepatic steatosis in liver transplantation. This article reviews the research progress of the above clinical methods in assessing the quality of donor liver with steatosis, and analyzes their advantages and disadvantages in clinical application, and provides a reference for the safe, rapid and non-invasive assessment of donor liver with steatosis.

Key words: Living liver transplantation, Fatty liver, Evaluation method, Steatosis

Jinping Zhang, Zhijun Zhu, Liying Sun, Lin Wei, Wei Qu, Zhigui Zeng, Haiming Zhang. Research progress of hepatic steatosis evaluation evaluate in living donor liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(04): 249-255.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2022.04.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2022/V16/I04/249

References 89

1	Moon DB, Lee SG. Liver transplantation[J]. Gut Liver, 2009, 3(3):145-165.
2	Urena MA, Moreno Gonzalez E, Romero CJ, et al. An approach to the rational use of steatotic donor livers in liver transplantation[J]. Hepatogastroenterology, 1999, 46(26):1164-1173.
3	Midia M, Odedra D, Shuster A, et al. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review[J]. Diagn Interv Radiol, 2019, 25(1):71-80.
4	West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies[J]. Gastroenterology, 2010, 139(4):1230-1237.
5	Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection[J]. J Gastrointest Surg, 1998, 2(3):292-298.
6	Soejima Y, Shimada M, Suehiro T, et al. Use of steatotic graft in living-donor liver transplantation[J]. Transplantation, 2003, 76(2):344-348.
7	Todo S, Demetris AJ, Makowka L, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration[J]. Transplantation, 1989, 47(5):903-905.
8	Adam R, Reynes M, Johann M, et al. The outcome of steatotic grafts in liver transplantation[J]. Transplant Proc, 1991, 23(1 Pt 2):1538-1540.
9	Hayashi M, Fujii K, Kiuchi T, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation[J]. Transplant Proc, 1999, 31(1-2):403.
10	Kwon CH, Joh JW, Lee KW, et al. Safety of donors with fatty liver in liver transplantation[J]. Transplant Proc, 2006, 38(7):2106-2107.
11	Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation[J]. Hepatology, 1994, 20(4 Pt 1):829-838.
12	Chu MJ, Dare AJ, Phillips AR, et al. Donor hepatic steatosis and outcome after liver transplantation: a systematic review[J]. J Gastrointest Surg, 2015, 19(9):1713-1724.
13	Angele MK, Rentsch M, Hartl WH, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation[J]. Am J Surg, 2008, 195(2):214-220.
14	Ploeg RJ, D′Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis[J]. Transplantation, 1993, 55(4):807-813.
15	Nikeghbalian S, Nejatollahi SM, Salahi H, et al. Does donor′s fatty liver change impact on early mortality and outcome of liver transplantation[J]. Transplant Proc, 2007, 39(4):1181-1183.
16	Fan ST, Lo CM, Liu CL, et al. Safety of donors in live donor liver transplantation using right lobe grafts[J]. Arch Surg, 2000, 135(3):336-340.
17	Ureña MA, Ruiz-Delgado FC, González EM, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program[J]. Transplant Proc, 1998, 30(7):3288-3291.
18	刘文娟，王丽华. 经颅多普勒超声诊断合并非酒精性脂肪肝的急性脑梗死患者的作用价值分析[J]. 脑与神经疾病杂志，2019, 27(12):4.
19	Paige JS, Bernstein GS, Heba E, et al. A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease[J]. AJR Am J Roentgenol, 2017, 208(5):W168-W177.
20	Bohte AE, Koot BG, van der Baan-Slootweg OH, et al. US cannot be used to predict the presence or severity of hepatic steatosis in severely obese adolescents[J]. Radiology, 2012, 262(1):327-334.
21	Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis[J]. World J Gastroenterol, 2019, 25(40):6053-6062.
22	Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations[J]. J Hepatol, 2010, 52(4):579-585.
23	van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved ¹H MR spectroscopy[J]. Radiology, 2010, 256(1):159-168.
24	Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis[J]. Dig Liver Dis, 2006, 38(7):485-489.
25	Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease[J]. Gastroenterology, 2002, 123(3):745-750.
26	Bamber JC, Hill CR, King JA. Acoustic properties of normal and cancerous human liver-II. Dependence of tissue structure[J]. Ultrasound Med Biol, 1981，7(2):135-144.
27	Chen CF, Robinson DE, Wilson LS, et al. Clinical sound speed measurement in liver and spleen in vivo[J]. Ultrason Imaging, 1987, 9(4):221-235.
28	Goss SA, Johnston RL, Dunn F. Comprehensive compilation of empirical ultrasonic properties of mammalian tissues[J]. J Acoust Soc Am, 1978, 64(2):423-457.
29	O′Brien WD Jr, Erdman JW Jr, Hebner TB. Ultrasonic propagation properties (@ 100 MHz) in excessively fatty rat liver[J]. J Acoust Soc Am, 1988, 83(3):1159-1166.
30	Imbault M, Faccinetto A, Osmanski BF, et al. Robust sound speed estimation for ultrasound-based hepatic steatosis assessment[J]. Phys Med Biol, 2017, 62(9):3582-3598.
31	Lin SC, Heba E, Wolfson T, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique[J]. Clin Gastroenterol Hepatol, 2015, 13(7):1337-1345.e6.
32	Han A, Andre MP, Erdman JW, et al. Repeatability and reproducibility of a clinically based QUS phantom study and methodologies[J]. IEEE Trans Ultrason Ferroelectr Freq Control, 2017, 64(1):218-231.
33	Hong YM, Yoon KT, Cho M, et al. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant[J]. Eur J Gastroenterol Hepatol, 2017, 29(7):805-810.
34	Mancia C, Loustaud-Ratti V, Carrier P, et al. Controlled attenuation parameter and liver stiffness measurements for steatosis assessment in the liver transplant of brain dead donors[J]. Transplantation, 2015, 99(8):1619-1624.
35	Nam K, Rosado-Mendez IM, Wirtzfeld LA, et al. Comparison of ultrasound attenuation and backscatter estimates in layered tissue-mimicking phantoms among three clinical scanners[J]. Ultrason Imaging, 2012, 34(4):209-221.
36	Haberal KM, Turnaoğlu H, Haberal Reyhan AN. Is unenhanced computed tomography reliable in the assessment of macrovesicular steatosis in living liver donors？[J]. Exp Clin Transplant, 2019, 17(6):749-752.
37	Zheng D, Tian W, Zheng Z, et al. Accuracy of computed tomography for detecting hepatic steatosis in donors for liver transplantation: a meta-analysis[J]. Clin Transplant, 2017, 31(8):10.1111/ctr.13013.
38	Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(23):7392-7402.
39	Yen YH, Kuo FY, Lin CC, et al. Predicting hepatic steatosis in living liver donors via controlled attenuation parameter[J]. Transplant Proc, 2018, 50(10):3533-3538.
40	Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings[J]. Radiology, 2004, 230(1):276-280.
41	Hamer OW, Aguirre DA, Casola G, et al. Imaging features of perivascular fatty infiltration of the liver: initial observations[J]. Radiology, 2005, 237(1):159-169.
42	Moon SK, Park YH, Moon DB, et al. How to perform selective liver biopsy in living liver donors using plain computed tomography[J]. Transplantation, 2016, 100(11):2398-2403.
43	Raptopoulos V, Karellas A, Bernstein J, et al. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses[J]. AJR Am J Roentgenol, 1991, 157(4):721-725.
44	Mendler MH, Bouillet P, Le Sidaner A, et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload[J]. J Hepatol, 1998, 28(5):785-794.
45	Ma X, Holalkere NS, Kambadakone RA, et al. Imaging-based quantification of hepatic fat: methods and clinical applications[J]. Radiographics, 2009, 29(5):1253-1277.
46	Lee SW, Park SH, Kim KW, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index[J]. Radiology, 2007, 244(2):479-485.
47	Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment[J]. Radiology, 2006, 239(1):105-112.
48	Kodama Y, Ng CS, Wu TT, et al. Comparison of CT methods for determining the fat content of the liver[J]. AJR Am J Roentgenol, 2007, 188(5):1307-1312.
49	Kim DY, Park SH, Lee SS, et al. Contrast-enhanced computed tomography for the diagnosis of fatty liver: prospective study with same-day biopsy used as the reference standard[J]. Eur Radiol, 2010, 20(2):359-366.
50	Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT[J]. AJR Am J Roentgenol, 1998, 171(3):659-664.
51	Johnston RJ, Stamm ER, Lewin JM, et al. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements[J]. Abdom Imaging, 1998, 23(4):409-415.
52	Iwasaki M, Takada Y, Hayashi M, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation[J]. Transplantation, 2004, 78(10):1501-1505.
53	Panicek DM, Giess CS, Schwartz LH. Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen？[J]. J Comput Assist Tomogr, 1997, 21(5):699-705.
54	Wang B, Gao Z, Zou Q, et al. Quantitative diagnosis of fatty liver with dual-energy CT. An experimental study in rabbits[J]. Acta Radiol, 2003, 44(1):92-97.
55	Artz NS, Hines CD, Brunner ST, et al. Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse[J]. Invest Radiol, 2012, 47(10):603-610.
56	Choudhary NS, Saraf N, Saigal S, et al. Prediction of nonalcoholic fatty liver in prospective liver donors[J]. Clin Transplant, 2017, 31(4):10.1111/ctr.12890.
57	Jehangir M, Nazir R, Jang A, et al. Macrovesicular steatosis in living related liver donors: correlation of biopsy findings with CT liver attenuation index and body mass index[J]. Clin Transplant, 2016, 30(9):1016-1020.
58	Adalı G, Bozkurt B, Ceyhan Ö，et al. Body mass index and unenhanced CT as a predictor of hepatic steatosis in potential liver donors[J]. Transplant Proc, 2019, 51(7):2373-2378.
59	Chiang HJ, Chang WP, Chiang HW, et al. Magnetic resonance spectroscopy in living-donor liver transplantation[J]. Transplant Proc, 2016, 48(4):1003-1006.
60	Zheng D, Guo Z, Schroder PM, et al. Accuracy of MR imaging and MR spectroscopy for detection and quantification of hepatic steatosis in living liver donors: a meta-analysis[J]. Radiology, 2017, 282(1):92-102.
61	Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance[J]. J Hepatol, 2009, 51(3):433-445.
62	Namimoto T, Yamashita Y, Mitsuzaki K, et al. Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas[J]. Radiology, 2001, 218(3):642-646.
63	Fishbein MH, Stevens WR. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver[J]. Pediatr Radiol, 2001, 31(11):806-809.
64	Kang BK, Yu ES, Lee SS, et al. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard[J]. Invest Radiol, 2012, 47(6):368-375.
65	McPherson S, Jonsson JR, Cowin GJ, et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered[J]. J Hepatol, 2009, 51(2):389-397.
66	Westphalen AC, Qayyum A, Yeh BM, et al. Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging[J]. Radiology, 2007, 242(2):450-455.
67	Yokoo T, Bydder M, Hamilton G, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T[J]. Radiology, 2009, 251(1):67-76.
68	Yokoo T, Shiehmorteza M, Hamilton G, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T[J]. Radiology, 2011, 258(3):749-759.
69	Lee SS, Lee Y, Kim N, et al. Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease[J]. J Magn Reson Imaging, 2011, 33(6):1390-1398.
70	Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy[J]. Radiology, 2009, 250(1):95-102.
71	O′Regan DP, Callaghan MF, Wylezinska-Arridge M, et al. Liver fat content and T2^*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T-feasibility[J]. Radiology, 2008, 247(2):550-557.
72	Urdzik J, Bjerner T, Wanders A, et al. The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis[J]. J Hepatol, 2012, 56(3):640-646.
73	Roldan-Valadez E, Favila R, Martínez-López M, et al. In vivo 3 T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: correlation with biochemical method and morphometry[J]. J Hepatol, 2010, 53(4):732-737.
74	Raptis DA, Fischer MA, Graf R, et al. MRI: the new reference standard in quantifying hepatic steatosis？[J]. Gut, 2012, 61(1):117-127.
75	Bottomley PA. Spatial localization in NMR spectroscopy in vivo[J]. Ann N Y Acad Sci, 1987, 508:333-348.
76	Frahm J, Bruhn H, Gyngell ML, et al. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo[J]. Magn Reson Med, 1989, 9(1):79-93.
77	Hamilton G, Middleton MS, Bydder M, et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification[J]. J Magn Reson Imaging, 2009, 30(1):145-152.
78	Reeder SB, Cruite I, Hamilton G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy[J]. J Magn Reson Imaging, 2011, 34(4):729-749.
79	Orlacchio A, Bolacchi F, Cadioli M, et al. Evaluation of the severity of chronic hepatitis C with 3-T¹H-MR spectroscopy[J]. AJR Am J Roentgenol, 2008, 190(5):1331-1339.
80	Cho SG, Kim MY, Kim HJ, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings[J]. Radiology, 2001, 221(3):740-746.
81	Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population[J]. BMC Gastroenterol, 2006, 6:33.
82	Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42(7):503-508.
83	Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors[J]. Gastroenterology, 2009, 137(3):865-872.
84	Yip TC, Ma AJ, Wong VW, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population[J]. Aliment Pharmacol Ther, 2017, 46(4):447-456.
85	Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis[J]. Comp Hepatol, 2005, 4:10.
86	Otgonsuren M, Estep MJ, Hossain N, et al. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [J]. J Gastroenterol Hepatol, 2014, 29(12):2006-2013.
87	He L, Deng L, Zhang Q, et al. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Biomed Res Int, 2017:9729107.
88	Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling[J]. Cell Metab, 2009, 9(2):125-139.
89	Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis[J]. J Hepatol, 2014, 61(6):1365-1375.

[1]	Tingting Liu, Yanbing Lin, Shan Wang, Murong Chen, Zijian Tang, Dongling Dai, Bei Xia. Evaluation of metabolic dysfunction-associated fatty liver disease in children by ultrasound-guided attenuation parameter [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 787-794.
[2]	Xin Wan, Qiuxia He, Mingming Li, Shouzhi Wang, Xi Chen, Xiuhua Yang. Correlative factors analysis in evaluating hepatic steatosis by ultrasound attenuation imaging technology [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(01): 57-62.
[3]	Chiyi Liu, Binfei Li, Chen Gu. Progress of perioperative anesthesia management in patients with frailty [J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(03): 236-240.
[4]	Jiahao Pei, Conghuan Shen, Ruidong Li, Yifeng Tao, Xinbao Xie, Weiming Chen, Zhengxin Wang. Efficacy of living liver transplantation in the treatment of pediatric acute liver failure and chronic end-stage liver disease [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(06): 329-333.
[5]	Group of Surgical Operation, Group of Organ Transplantation, Society of Surgery, Chinese Medical Association. Expert consensus on assessment of donor and liver graft for split liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(02): 133-138.
[6]	Liye Liu, Defang Zhao. Correlations between serum SOCS3 and LXRαlevels and CT imaging features in patients with non-alcoholic fatty liver disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 211-215.
[7]	Guoying Zhu, Li Chen, Ling She, Jie Bai, Yongnian Ding, Fengshang Zhu. Therapeutic reality and dilemma of microecological modulators in patients with non-alcoholic fatty liver disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(01): 1-4.
[8]	Guoying Zhu, Li Chen, Yongnian Ding, Changqing Yang, Fengshang Zhu. Pay attention to basic and clinical research of fatty pancreas [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(03): 129-132.
[9]	Fanbiao Kong, Jianrong Yang. Progress in understanding of relationship between underlying liver diseases and liver metastasis of colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 818-822.
[10]	Daya Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Da Li, Feihu Bai. Role of intestinal microecological dysregulation in development of metabolic-associated fatty liver disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 828-833.
[11]	Wenwen Ma, Min Hu, Guihong Wang, Jian Gao. Significance of expression of miR-103a-2, miR-122, and vaspin in non-alcoholic fatty liver disease with HBV infection [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(02): 170-174.
[12]	Haiyan Lin, Ning Cheng, Xin Huang, Wei Liu, Yuanyuan Wang. Effect of self-made Shugan Jianpi prescription on short chain fatty acids in patients with non-alcoholic fatty liver of stagnation of liver qi and spleen deficiency type [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(11): 871-876.
[13]	Weiting Lu, Huilian Shi, Qinlei Chen, Jianhai Wu, Shaowei Liu, Fei Qiao. Characteristics of magnetic resonance imaging proton density fat fraction in patients with metabolic associated fatty liver disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(07): 503-508.
[14]	Meiyu Zhang, Shengli Wu, Weiting Xiang, Kehong Sun, Nong Li. The diagnostic value of the triglyceride-glucose index in predicting the risk of non-alcoholic fatty liver disease in physical examination population [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(03): 152-157.
[15]	Yawei He, Wanjing Chen, Jiahong Song, Gang Yu, Benli Jia, Yong Wang. Study on the relationship between SCH, serum vitamin D levels and the severity of NAFLD in patients with obesity [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(02): 95-101.

Please choose a citation manager

Content to export